Clearside Biomedical (CLSD) has released an update to notify the public and investors about an entry into a material definitive agreement.
Clearside Biomedical, Inc., Emory University, and Georgia Tech Research Corporation amended their 2012 License Agreement on January 31, 2024. The amendment adjusted the sublicense percentage fees payable to the licensor from a low double-digit to a high single-digit percentage of sublicensee payments received after July 1, 2023, and set a deadline for such payments by March 31, 2025, for payments received before January 1, 2025. It also established a revised annual license maintenance fee schedule ranging from $250,000 to $500,000 for the years 2023 through 2028. All other terms, including the royalty rate, remained unchanged.
For further insights into CLSD stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
